Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yun Fan

Showing results (861-870 of 920) with videos related to

Pageof 92
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2024
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i>-Mutant, Metastatic Nonsquamous Non-Small Cell Lung CancerJames Chih-Hsin Yang, Dae Ho Lee, Jong-Seok Lee, et al.
Hepatology Communications|June 9, 2018
Metabolic risk factors are associated with non-hepatitis B non-hepatitis C hepatocellular carcinoma in Taiwan, an endemic area of chronic hepatitis BShiu-Feng Huang, Il-Chi Chang, Chih-Chen Hong, et al.
Clinical and Translational Medicine|December 17, 2024
PARylation of HMGA1 desensitizes esophageal squamous cell carcinoma to olaparibXin-Yuan Lei, Kai-Yue He, Qiu-Tong Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 26, 2024
Vebreltinib for Advanced Non-Small Cell Lung Cancer Harboring c-Met Exon 14 Skipping Mutation: A Multicenter, Single-Arm, Phase II KUNPENG StudyJin-Ji Yang, Yan Zhang, Lin Wu, et al.
JAMA Oncology|June 26, 2025
High-Dose Aumolertinib for Untreated EGFR-Variant Non-Small Cell Lung Cancer With Brain Metastases: The ACHIEVE Phase 2 Nonrandomized Clinical TrialHui Li, Kaiyan Chen, Lei Gong, et al.
The Lancet. Oncology|December 9, 2025
Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 studyYi-Long Wu, Yu Yao, Jin-Ji Yang, et al.
Nature Medicine|April 10, 2025
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trialsShen Zhao, Ying Cheng, Qiming Wang, et al.
Medicine|April 16, 2016
The Hepatitis Viral Status in Patients With Hepatocellular Carcinoma: a Study of 3843 Patients From Taiwan Liver Cancer NetworkIl-Chi Chang, Shiu-Feng Huang, Pei-Jer Chen, et al.
Journal of Gastroenterology and Hepatology|July 9, 2002
Eight-year nationwide survival analysis in relatives of patients with hepatocellular carcinoma: role of viral infectionDar-In Tai, Chien-Hung Chen, Ting-Tsung Chang, et al.
The Lancet. Oncology|May 16, 2022
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialJie Wang, Caicun Zhou, Wenxiu Yao, et al.
Pageof 92

Showing results (861-870 of 920) with videos related to

Sort By:
Pageof 92
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2024
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i>-Mutant, Metastatic Nonsquamous Non-Small Cell Lung CancerJames Chih-Hsin Yang, Dae Ho Lee, Jong-Seok Lee, et al.
Hepatology Communications|June 9, 2018
Metabolic risk factors are associated with non-hepatitis B non-hepatitis C hepatocellular carcinoma in Taiwan, an endemic area of chronic hepatitis BShiu-Feng Huang, Il-Chi Chang, Chih-Chen Hong, et al.
Clinical and Translational Medicine|December 17, 2024
PARylation of HMGA1 desensitizes esophageal squamous cell carcinoma to olaparibXin-Yuan Lei, Kai-Yue He, Qiu-Tong Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 26, 2024
Vebreltinib for Advanced Non-Small Cell Lung Cancer Harboring c-Met Exon 14 Skipping Mutation: A Multicenter, Single-Arm, Phase II KUNPENG StudyJin-Ji Yang, Yan Zhang, Lin Wu, et al.
JAMA Oncology|June 26, 2025
High-Dose Aumolertinib for Untreated EGFR-Variant Non-Small Cell Lung Cancer With Brain Metastases: The ACHIEVE Phase 2 Nonrandomized Clinical TrialHui Li, Kaiyan Chen, Lei Gong, et al.
The Lancet. Oncology|December 9, 2025
Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 studyYi-Long Wu, Yu Yao, Jin-Ji Yang, et al.
Nature Medicine|April 10, 2025
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trialsShen Zhao, Ying Cheng, Qiming Wang, et al.
Medicine|April 16, 2016
The Hepatitis Viral Status in Patients With Hepatocellular Carcinoma: a Study of 3843 Patients From Taiwan Liver Cancer NetworkIl-Chi Chang, Shiu-Feng Huang, Pei-Jer Chen, et al.
Journal of Gastroenterology and Hepatology|July 9, 2002
Eight-year nationwide survival analysis in relatives of patients with hepatocellular carcinoma: role of viral infectionDar-In Tai, Chien-Hung Chen, Ting-Tsung Chang, et al.
The Lancet. Oncology|May 16, 2022
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialJie Wang, Caicun Zhou, Wenxiu Yao, et al.
Pageof 92